Study;Selection;Comparability;Exposure/Outcome;"Overall rating (NOS)"
"Jilla et al.[14] (2022, India)";"++++ Clear patient selection, well-defined criteria, large sample size (n=46)";"++ Comparison by treatment groups";"+++ Accurate follow-up for outcomes";9/9
"Brown et al.[15] (2022, UK)";"++++ Consecutive series of 490 patients, clear inclusion/exclusion";"++ Adjusted for key covariates";"++ OS and survival predictors assessed with robust methods";8/9
"Vaz-Salgado et al.[16] (2023, Spain)";"+++ Comprehensive selection but small sample size (n=90)";"++ Comparability of treatment modalities";"++ Detailed outcomes including OS and PFS";7/9
"Fekete et al.[17] (2023, Sweden)";"++++ Clear selection criteria, large cohort (n=222)";"++ Adjusted for covariates";"++ Accurate follow-up, survival analyzed with robust methods";8/9
"Hansen et al.[18] (2024, Denmark)";"+++ Small sample size (n=66), clear criteria";"++ Adjusted by prognostic scale";"+++ Detailed follow-up, survival data collected";7/9
"Fu et al.[2] (2024, China)";"++++ Large sample (n=126), well-defined selection";"++ Adjusted for key variables";"++ Clear reporting of survival and risk groups";8/9
"Van Linde et al.[12] (2017, Netherlands)";"++++ Clear selection, large cohort (n=299)";"++ Adjusted for multiple clinical variables";"++ Detailed follow-up, clear outcomes measured";9/9
"Audureau et al.[13] (2017, France)";"++++ Comprehensive selection (n=407), multicenter";"++ Adjusted for clinical and treatment factors";"+++ Decision tree and survival outcomes tracked";9/9
"Karschnia et al.[19] (2023, USA/Germany)";"++++ Large sample size (681), robust selection, detailed clinical data";"++ Stratification by RANO classification and other key clinical variables";"+++ Accurate survival and progression tracking";9/9
"Blakstad et al.[20] (2023, Norway)";"++++ Consecutive series of 467 patients, comprehensive data";"++ Adjusted for age, MGMT methylation, extent of resection";"++ Detailed survival outcomes, clear follow-up";8/9
"Schaub et al.[21] (2016, Germany)";"+++ Well-defined cohort (174), detailed inclusion criteria";"++ Comparison by treatment with or without irinotecan";"++ Clear follow-up, OS and PFS tracked";8/9